Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found tha...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Virol
Autori principali: Quashie, Peter K., Oliviera, Maureen, Veres, Tamar, Osman, Nathan, Han, Ying-Shan, Hassounah, Said, Lie, Yolanda, Huang, Wei, Mesplède, Thibault, Wainberg, Mark A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2014
Soggetti:
Vaccines and Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337543/
https://ncbi.nlm.nih.gov/pubmed/25552724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.03353-14
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi